Last reviewed · How we verify
Continue the antimicrobial treatment — Competitive Intelligence Brief
phase 3
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
Continue the antimicrobial treatment (Continue the antimicrobial treatment) — Assistance Publique - Hôpitaux de Paris. This is a treatment directive to continue an existing antimicrobial regimen rather than a specific drug entity.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Continue the antimicrobial treatment TARGET | Continue the antimicrobial treatment | Assistance Publique - Hôpitaux de Paris | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Continue the antimicrobial treatment CI watch — RSS
- Continue the antimicrobial treatment CI watch — Atom
- Continue the antimicrobial treatment CI watch — JSON
- Continue the antimicrobial treatment alone — RSS
Cite this brief
Drug Landscape (2026). Continue the antimicrobial treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/continue-the-antimicrobial-treatment. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab